What is ARCUS?

ARCUS is Precision BioSciences’ unique, highly specific and versatile genome editing platform.

Designed for Therapeutic-Grade Editing

Precision’s proprietary ARCUS® platform is designed to deliver therapeutic-grade genome editing. In contrast to editing platforms that focus on ease of design and quick turnaround, the ARCUS approach is centered on safety, delivery, and control of edits – the things that we believe matter most to patients and their physicians. ARCUS nucleases have the potential to deliver safer, more specific genetic edits by leveraging the properties of a naturally occurring gene editing enzyme – the homing endonuclease I-CreI – which evolved in nature to make a single, highly specific DNA edit before using its built-in safety switch to shut itself off.

The ARCUS Advantage

The built-in safety switch is a key differentiator and one reason why we believe ARCUS reduces the risk of additional, off-target DNA edits, a significant limitation of other gene editing technologies. ARCUS is also significantly smaller than other gene editing technologies, with a length of only 364 amino acids, which makes it easier to deliver to specific tissues and cells. The innovative design of the ARCUS nuclease is the basis for over 50 US and foreign patents.

What makes ARCUS unique in the world of genome editing?


Precision BioSciences owns ARCUS. Only a Precisioneer can make an ARCUS reagent.


ARCUS isn’t limited to deletions. ARCUS can be used to insert, delete or edit DNA.


ARCUS doesn’t miss its target. ARCUS doesn’t generate truly random DNA-breaks.


364 amino acids. 1092 base pairs. ARCUS is compatible with essentially any delivery strategy.


Polypeptide. ARCUS is a single protein expressed from a single gene. There’s no need to deliver multiple parts.


Matched 4 base pair 3′ overhangs result in perfect, predictable removal of DNA.